GlaxoSmithKline gearing up for Alli launch

Share this article:

GlaxoSmithKline continues to prepare for the rollout of its new OTC diet pill Alli.

The UK drugmaker is scheduled to begin shipping Alli to US pharmacies today, with the weight loss remedy expected to officially go on sale next Monday.

Early demand from retailers has been strong from retailers, including Wal-Mart Stores, and 400,000 Alli starter kits are being shipped to fill the supply chain.

Analysts estimate the launch of Alli will be one of the biggest ever for an OTC medicine. GlaxoSmithKline is spending an estimated $150 million on marketing in the US.

Alli will retail for between $55 and $60 for a month’s supply, based on a regimen of three pills a day.

Citigroup estimates global Alli sales could hit $724 million by 2011.

Share this article:
You must be a registered member of MMM to post a comment.

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...